Tryngolza (FCS)

Get notified when a new coverage update is posted for this brand.

Therapeutic Area

Rare Disease / Lipidology — Familial Chylomicronemia Syndrome

Primary Competitor

Waylivra

Current Watch Item

Genetic confirmation criteria

Payers with Published Policy

4tracked in database

4 backed by a citable published policy document

PA Criteria Defined

46%of published policies

Exception Pathway Published

22%of published policies

Time to First Policy

6 momedian since launch
AI SUMMARY

Brand Access Summary

Tryngolza (FCS) policy is emerging slowly given the ultra-rare eligible population. Where policy exists, genetic or biochemical confirmation of LPL deficiency is the dominant gate — the near-term goal is getting more payers to publish criteria at all, not fine-tuning existing ones.

Indication-centered view

Policy Posture and UM Summary

SEGMENTPOLICY POSTURECOMMON UM CRITERIALAUNCH RISK
Commercial54% published / 44% PA definedGenetic/biochemical LPL deficiency confirmation; lipidologist attestationWhitespace exceeds published policy — most commercial books have not decided
Medicare61% published / 50% PA definedDiagnosis confirmation plus TG history documentationSmall eligible population means slow policy movement even where covered
Medicaid39% published / 28% PA definedState-by-state genetic testing coverage varies independently of drug policyGenetic test access itself can gate the pathway before drug PA is even reached

Access build since launch

Launch Access Trend

Policy publishedPA criteria definedNo policyException pathway
100%50%0%M1M4M8M12M18M24

Brand documents

Shared Documents

PDF, DOC, PNG or JPG · max 20 MB

Policy PDF — Iowa Medicaid

Uploaded by Priya Shah

Jun 1, 2026

PA Form — Humana

Uploaded by Marcus Allen

May 22, 2026

Field Intake Note — Aetna

Uploaded by Elena Garcia

Jun 3, 2026